Products

Therapeutic Protein/Peptide Component:

Indication(s): 

Owner

Key Attributes:

Development Status:

• Ability to maintain serum levels for more than 2 weeks with a low peak/trough ratio
  (potential for reduced gastrointestinal side effects)
• Prolonged half-life to enable dosing every 2-4 weeks in humans
• Stable liquid small volume injection (27-30 G needle) administered with autoinjector

• Preclinical studies completed in mice, rats, dogs, and monkeys
• Pharmacokinetics in all species
• Proof of concept efficacy in normal mice (glucose challenge) and ob/ob mice
• Non-GLP single dose toxicology in rats